Renguo Guan

1.1k total citations
32 papers, 639 citations indexed

About

Renguo Guan is a scholar working on Hepatology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Renguo Guan has authored 32 papers receiving a total of 639 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hepatology, 13 papers in Molecular Biology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Renguo Guan's work include Hepatocellular Carcinoma Treatment and Prognosis (16 papers), Ferroptosis and cancer prognosis (8 papers) and RNA modifications and cancer (7 papers). Renguo Guan is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (16 papers), Ferroptosis and cancer prognosis (8 papers) and RNA modifications and cancer (7 papers). Renguo Guan collaborates with scholars based in China and Hong Kong. Renguo Guan's co-authors include Min Yu, Weifeng Hong, Ye Lin, Haosheng Jin, Liheng Ma, Lei Tu, Baohua Hou, Rong Guo, Zhixiang Jian and Min Deng and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and International Journal of Cancer.

In The Last Decade

Renguo Guan

31 papers receiving 633 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Renguo Guan China	14	296	225	210	165	153	32	639
Longzi Liu China	11	436 1.5×	311 1.4×	337 1.6×	148 0.9×	288 1.9×	12	878
Hengkang Liu China	6	264 0.9×	263 1.2×	170 0.8×	105 0.6×	280 1.8×	6	637
Antonio Cusmai Italy	11	197 0.7×	292 1.3×	109 0.5×	124 0.8×	138 0.9×	28	577
A. Reinacher-Schick Germany	11	175 0.6×	441 2.0×	149 0.7×	146 0.9×	61 0.4×	46	636
Guijuan Luo China	10	443 1.5×	133 0.6×	317 1.5×	181 1.1×	94 0.6×	12	645
Giulia Orsi Italy	12	171 0.6×	220 1.0×	113 0.5×	148 0.9×	38 0.2×	34	514
Anna Kan China	16	331 1.1×	275 1.2×	244 1.2×	173 1.0×	136 0.9×	38	927
Laura July Canada	7	252 0.9×	339 1.5×	141 0.7×	148 0.9×	99 0.6×	9	623
F. De Vita Italy	11	198 0.7×	405 1.8×	220 1.0×	196 1.2×	53 0.3×	37	691
Chang-Long Chen China	14	206 0.7×	357 1.6×	130 0.6×	106 0.6×	220 1.4×	17	611

Countries citing papers authored by Renguo Guan

Since Specialization

Citations

This map shows the geographic impact of Renguo Guan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Renguo Guan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Renguo Guan more than expected).

Fields of papers citing papers by Renguo Guan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Renguo Guan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Renguo Guan. The network helps show where Renguo Guan may publish in the future.

Co-authorship network of co-authors of Renguo Guan

This figure shows the co-authorship network connecting the top 25 collaborators of Renguo Guan. A scholar is included among the top collaborators of Renguo Guan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Renguo Guan. Renguo Guan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Deng, Min, Rongce Zhao, Hao Zou, et al.. (2025). Oxaliplatin induces pyroptosis in hepatoma cells and enhances antitumor immunity against hepatocellular carcinoma. British Journal of Cancer. 132(4). 371–383. 2 indexed citations

Guan, Renguo, et al.. (2025). Assessment of Tumor Burden Score as a Feasible and Reliable Tool for Prognosis Prediction for Hepatocellular Carcinoma Undergoing Hepatectomy: A Multicenter, Retrospective Study. Journal of Hepatocellular Carcinoma. Volume 12. 247–260. 1 indexed citations

Guan, Renguo, Rongce Zhao, Jingwen Zou, et al.. (2025). Prognosis prediction of α-FAtE score for locoregional immunotherapy in hepatocellular carcinoma. Frontiers in Immunology. 15. 1496095–1496095. 2 indexed citations

Lu, Lianghe, Jie Mei, Yihong Ling, et al.. (2024). Hepatic Arterial Infusion Chemotherapy vs Transcatheter Arterial Chemoembolization as Adjuvant Therapy Following Surgery for MVI-Positive Hepatocellular Carcinoma: A Multicenter Propensity Score Matching Analysis. Journal of Hepatocellular Carcinoma. Volume 11. 665–678. 4 indexed citations

Fu, Yizhen, Shiliang Liu, Renguo Guan, et al.. (2024). Comparison of resection, ablation, and stereotactic body radiation therapy in treating solitary hepatocellular carcinoma ≤5 cm: a retrospective, multicenter, cohort study. International Journal of Surgery. 111(1). 1535–1540. 4 indexed citations

Mei, Jie, et al.. (2024). A novel liver-function-indicators-based prognosis signature for patients with hepatocellular carcinoma treated with anti-programmed cell death-1 therapy. Cancer Immunology Immunotherapy. 73(8). 158–158. 3 indexed citations

Guan, Renguo, Jie Mei, Wen‐Ping Lin, et al.. (2023). Is the CRAFITY score a superior predictor of prognosis and adverse events in hepatocellular carcinoma patients treated with locoregional-immunotherapy?. Hepatology International. 17(5). 1279–1288. 13 indexed citations

Deng, Min, Rongce Zhao, Renguo Guan, et al.. (2023). Development of nomograms to predict recurrence after conversion hepatectomy for hepatocellular carcinoma previously treated with transarterial interventional therapy. European journal of medical research. 28(1). 328–328. 3 indexed citations

Li, Shaohua, Jie Mei, Qiaoxuan Wang, et al.. (2023). Comparison of anti–PD-L1 with anti–PD-1 antibodies in the combination of HAIC and lenvatinib for the treatment of unresectable hepatocellular carcinoma.. Journal of Clinical Oncology. 41(4_suppl). 509–509. 2 indexed citations

10.

Deng, Min, et al.. (2023). Hepatic arterial infusion chemotherapy versus transarterial chemoembolization, potential conversion therapies for single huge hepatocellular carcinoma: a retrospective comparison study. International Journal of Surgery. 109(11). 3303–3311. 18 indexed citations

11.

Guan, Renguo, et al.. (2022). Microvascular Invasion in Hepatocellular Carcinoma: A Review of Its Definition, Clinical Significance, and Comprehensive Management. Journal of Oncology. 2022. 1–10. 33 indexed citations

12.

Guan, Renguo, Yiping Zou, Zhixiang Jian, et al.. (2022). Nomogram Based on Inflammatory Biomarkers to Predict the Recurrence of Hepatocellular Carcinoma—A Multicentre Experience. Journal of Inflammation Research. Volume 15. 5089–5102. 13 indexed citations

13.

Guan, Renguo, et al.. (2022). A preliminary study on drug switching strategy for second-line therapy after combination treatment of tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma. Frontiers in Pharmacology. 13. 998534–998534. 1 indexed citations

14.

Deng, Min, Rongce Zhao, Renguo Guan, et al.. (2022). The pyroptosis-related gene signature predicts prognosis and indicates immune activity in hepatocellular carcinoma. Molecular Medicine. 28(1). 16–16. 57 indexed citations

15.

Guan, Renguo, Jingwen Zou, Jie Mei, Min Deng, & Rong Guo. (2022). Four-gene signature predicting overall survival and immune infiltration in hepatocellular carcinoma by bioinformatics analysis with RT‒qPCR validation. BMC Cancer. 22(1). 830–830. 4 indexed citations

16.

Guan, Renguo, et al.. (2021). Development of a novel prognostic nomogram for the early recurrence of liver cancer after curative hepatectomy. Annals of Translational Medicine. 9(20). 1541–1541. 8 indexed citations

17.

Huang, Bowen, et al.. (2020). A Comprehensive Exploration of the lncRNA CCAT2: A Pan-Cancer Analysis Based on 33 Cancer Types and 13285 Cases. Disease Markers. 2020. 1–13. 5 indexed citations

18.

Lin, Ye, et al.. (2020). Long non-coding RNA DLGAP1-AS1 facilitates tumorigenesis and epithelial–mesenchymal transition in hepatocellular carcinoma via the feedback loop of miR-26a/b-5p/IL-6/JAK2/STAT3 and Wnt/β-catenin pathway. Cell Death and Disease. 11(1). 34–34. 78 indexed citations

19.

Hong, Weifeng, et al.. (2020). Pan-cancer analysis of the CASP gene family in relation to survival, tumor-infiltrating immune cells and therapeutic targets. Genomics. 112(6). 4304–4315. 26 indexed citations

20.

Tu, Lei, Renguo Guan, Yu Zhou, et al.. (2019). Assessment of the expression of the immune checkpoint molecules PD‐1, CTLA4, TIM‐3 and LAG‐3 across different cancers in relation to treatment response, tumor‐infiltrating immune cells and survival. International Journal of Cancer. 147(2). 423–439. 128 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact